18-Month Retrospective Claims Analysis Study Information on Ruxolitinib

Opinion
Video

Panelists discuss how the 18-month retrospective claims analysis of ruxolitinib revealed sustained efficacy in atopic dermatitis management, with significant reductions in disease flares, healthcare utilization, and concomitant medication use compared to conventional therapies, while maintaining a consistent safety profile across diverse patient populations and disease severities.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
2 experts in this video
Related Content
Exploring Real-World Atopic Dermatitis Treatment Patterns | Written Recap

Exploring Real-World Atopic Dermatitis Treatment Patterns | Written Recap

Peter Wehrwein, Managing Editor
September 16th 2025
Article

Read More

Stethoscope sitting on money | Image credit: Valeri Luzina - stock.adobe.com

Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease

Laura Joszt, MA
September 16th 2025
Article

Read More

A gene being edited | Image credit: natali_mis - stock.adobe.com

A Single CRISPR Treatment Could Replace a Lifetime of Daily Treatment in Hereditary Angioedema

Laura Joszt, MA
September 16th 2025
Article

Read More

GVHD wood blocks with pills | Image credit: Dzmitry - stock.adobe.com

New Chronic GVHD Treatments Show Promise, but Long-Term Outcomes Are Not Well Understood

Laura Joszt, MA
September 16th 2025
Article

Read More

Wooden blocks spelling GVHD | Image credit: Stanislau - adobe.stock.com

GVHD Cannot Be Wholly Prevented, so Effective Treatments Are Needed, Says Dr. Daniel Wolff

Laura Joszt, MA
September 16th 2025
Article

Read More

Screenshot of an interview with Michelle Cespedes, M.D.

Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024

Peter Wehrwein, Managing Editor;Laura Joszt, MA
September 16th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.